SciSparc Files US Patent for Weight Loss & Metabolic Syndrome Drug
Ticker: SPRC · Form: 6-K · Filed: Jul 16, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Jul 16, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent-application, pharmaceuticals, metabolic-syndrome, weight-loss
TL;DR
SciSparc filed a US patent for its SCI-110 combo drug targeting weight loss and metabolic syndrome.
AI Summary
On July 16, 2024, SciSparc Ltd. announced the filing of a U.S. patent application for its novel cannabinoid-based combination therapy aimed at treating metabolic syndrome and promoting weight loss. This application covers the use of their proprietary drug candidate, SCI-110, in combination with other compounds to address these conditions.
Why It Matters
This patent filing is significant as it could lead to exclusive rights for SciSparc's innovative treatment, potentially impacting the pharmaceutical market for metabolic disorders and obesity.
Risk Assessment
Risk Level: medium — Patent applications are not guarantees of approval or market success, and the development of new drugs faces significant regulatory and commercial hurdles.
Key Players & Entities
- SciSparc Ltd. (company) — The company filing the patent application.
- SCI-110 (drug_candidate) — SciSparc's proprietary drug candidate mentioned in the patent application.
- July 16, 2024 (date) — Date of the press release announcing the patent filing.
FAQ
What is the specific focus of the U.S. patent application filed by SciSparc?
The U.S. patent application filed by SciSparc focuses on a novel cannabinoid-based combination therapy for treating metabolic syndrome and promoting weight loss.
What is the name of SciSparc's proprietary drug candidate mentioned in the filing?
SciSparc's proprietary drug candidate mentioned in the filing is SCI-110.
On what date was the press release announcing the patent application issued?
The press release announcing the patent application was issued on July 16, 2024.
What conditions does SciSparc's new therapy aim to treat?
SciSparc's new therapy aims to treat metabolic syndrome and weight loss.
Under which rule is SciSparc Ltd. filing this Form 6-K?
SciSparc Ltd. is filing this Form 6-K pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 322 words · 1 min read · ~1 pages · Grade level 8.2 · Accepted 2024-07-16 09:25:02
Filing Documents
- ea0209489-6k_scisparc.htm (6-K) — 13KB
- ea020948901ex99-1_scisparc.htm (EX-99.1) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- 0001213900-24-061562.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: July 16, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3